Please assess the completion status of the following clinical trial:

Trial Title: Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female asthmatics \> 19 years of age~* baseline methacholine PC20 less than or equal to 4mg/ml~* baseline lung function \>65% predicted~* non-smoker and less than 10 pack year smoking history~Exclusion Criteria:~* use of anticholinergic within 30 days of Visit 1~* poorly controlled asthma~* pregnant or nursing~* respiratory illness within 4 weeks of Visit 1~* exposure to an agent that triggered asthma worsening (e.g. allergen) within 4 weeks of Visit 1

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium (Type: EXPERIMENTAL): 2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
- glycopyrronium (Type: EXPERIMENTAL): 1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge

Based on this trial design, predict the completion outcome and termination type (if applicable).